Repligen to Acquire BioLife Solutions in Cash and Stock Merger Valued at $11.25 Per Share

Merger Structure and Process

The acquisition will be completed via a two-step merger involving two wholly owned Repligen subsidiaries. Initially, Bravo Merger Sub I, Inc., a Delaware corporation and direct Repligen subsidiary, will merge into BioLife Solutions, with BioLife surviving as Repligen’s wholly owned subsidiary. Subsequently, BioLife will merge with Bravo Merger Sub II, LLC, with Merger Sub II surviving as a wholly owned Repligen subsidiary. This structure facilitates integration while maintaining operational continuity during the transition.

Boards of directors for both Repligen and BioLife have approved the Merger Agreement and related transactions. Both companies have made customary representations, warranties, and covenants, agreeing to operate in the ordinary course consistent with past practice between signing and closing. They commit to using reasonable best efforts to satisfy closing conditions and preserve their business organizations and material assets during this interim.

Details of Cash and Stock Consideration

BioLife shareholders will receive a combination of cash and equity consideration. The cash payment is fixed at $11.25 per share, paid without interest. The stock consideration is based on an exchange ratio of 0.1442 shares of Repligen common stock for each BioLife share outstanding at the effective time of the first merger. This hybrid consideration provides liquidity and ongoing equity participation in the merged company.

No fractional shares of Repligen stock will be issued. Instead, shareholders entitled to fractional shares will receive cash in lieu, as outlined in the Merger Agreement. This ensures administrative efficiency while fully compensating all shareholders.

Treatment of BioLife Equity Awards

Outstanding BioLife equity awards will accelerate upon closing. All BioLife options, vested or unvested, will fully vest immediately before the first merger effective time and be cancelled in exchange for a net-settled payment in BioLife common stock based on intrinsic value, less applicable withholding taxes.

Time-based restricted stock units (RSUs) will fully vest and be settled in BioLife common stock. Performance-based restricted stock units (PSUs) will also fully vest and be settled assuming the greater of target or actual performance achievement measured as of the latest practicable date before the merger. Unvested restricted stock awards (RSAs) will fully vest and be released. All shares issuable under these awards will convert automatically into the right to receive merger consideration at the first merger effective time, ensuring equity holders receive full value.

Shareholder and Regulatory Approvals

The merger closing requires approval by a majority of BioLife’s outstanding voting shares at a duly held shareholder meeting. Additionally, the issuance of Repligen shares in the first merger must be approved for listing on The Nasdaq Stock Market to comply with Nasdaq standards.

The transaction is subject to expiration or termination of the Hart-Scott-Rodino Act waiting period and receipt of required antitrust consents. The SEC must declare effective a Registration Statement on Form S-4 filed by Repligen, which includes the proxy statement and prospectus related to the merger. Immediate share price impact was not available at the time of announcement.

Representations, Warranties, and Covenants

Both companies have made customary representations and warranties covering organization, capitalization, authority, and absence of undisclosed liabilities. They have also agreed to covenants to conduct business in the ordinary course consistent with past practice during the interim period, subject to mutual consent for exceptions. These measures aim to preserve business value until closing.

Closing Conditions and Material Adverse Effect Clause

Closing is contingent on no adverse laws or orders preventing the merger and no continuing material adverse effect on either company. Certain materiality exceptions apply to representations, warranties, and covenants, though specifics were not detailed in the filing excerpt.

The parties expect to complete the merger in Q4 2026, pending regulatory filings, shareholder approval, and antitrust reviews. The exact closing date depends on timing of these approvals and absence of delays.

Business Profiles and Integration Outlook

Repligen Corporation specializes in bioprocessing and laboratory automation technology serving biopharmaceutical manufacturers and research organizations. BioLife Solutions focuses on biopreservation technologies within the biotech sector. Financial metrics were not disclosed in this announcement and are expected in future filings.

This transaction strategically combines complementary life sciences capabilities. Interim covenants indicate management intends to maintain operational integrity of both companies through closing. Investors should watch for upcoming disclosures, including the Form S-4, for further business strategy and financial details.

Investor Considerations and Outstanding Questions

The announcement did not disclose total transaction value, revenue comparisons, or financial projections for the combined entity. These details will likely be included in Repligen’s forthcoming Form S-4 registration statement. Investors should review that filing for comprehensive financial analysis and integration plans.

Timing of regulatory approvals such as Hart-Scott-Rodino clearance and Nasdaq listing remains unspecified. Delays could impact the anticipated Q4 2026 closing. Future updates will provide progress on regulatory and shareholder approvals. The Merger Agreement includes standard termination rights and fees, though details were not provided in this release.